凤凰网《风暴眼》出品 仅需数十万元，就能定制有百年老字号"北京同仁堂"品牌背书的保健品、滋补品、各类日用产品。这种低门槛、高灵活度的贴牌模式，使得电商平台上充斥 着五花八门的"同仁堂"产品，几乎到了"万物皆可贴"的地步。 凤凰网《风暴眼》从一名品牌授权招商人员黄兴（化名）处了解到，这种贴牌合作，起订量低至一万盒，由同仁堂合作工厂代工，可选择"蓝帽"（保健食 品）或"食品"标识，产品包装可使用"北京同仁堂"字样，只要注意字号比例，"绝对没问题"。 然而，正是这种贴牌产品，近日引发了不小的风波。一款标称"北京同仁堂高纯南极磷虾油"的产品，被曝核心成分磷脂含量为零，引发公众对同仁堂产品质 量的质疑。 图片来源：哈博药业官网 面对媒体，生产方哈博药业表示，"目前尚不清楚涉事产品是否为本公司生产，正在核查中"。 哈博药业是一家主营保健食品贴牌代加工（OEM/ODM）的服务商。天眼查显示，其存在多次行政处罚记录和食品安全问题。例如，2025年6月曾因广告引 证内容违反《广告法》第十一条规定行为被罚款一万元，其累计被罚金额27.8万元。2024年7月，其生产的锌镁片抽检不合格。 面对质疑声浪，同仁堂最终选择了"弃车保帅"， ...

需要强调的是，这一修复并非情绪驱动，而是建立在增长结构逐步清晰、业务可预期性提升的基础之 上。Swisse的体系化运营，使健合集团的估值逻辑开始从"修复假设"转向"数据验证"。 对于投资者而言，后续关注重点或不再只是短期增速，而在于：这一结构是否能够持续、子品牌能否稳 定贡献增量，以及体系优势是否进一步转化为盈利能力。这些因素，将决定健合集团估值中枢能否真正 抬升。 资本市场对健合集团的长期关注点，正在从历史问题转向增长确定性本身。而Swisse中国业务的变化， 是这一转向中的关键变量。 经过十年发展，Swisse已完成从市场导入到本土化体系成熟的转变，并逐步形成"主品牌稳态 + 子品牌 增量"的双层增长结构。这一结构意味着：即便行业整体需求波动，集团核心业务仍具备一定的防御属 性，同时保留向上弹性。 从经营层面看，Swisse在中国市场的持续增长，为集团账面商誉提供了更扎实的业绩支撑；从市场反馈 看，2025年以来健合集团股价累计涨幅超过40%，明显跑赢此前阶段的市场预期。 ...

12月15日，北京同仁堂健康药业股份有限公司发布声明： 近日，有媒体报道一款标注"安徽哈博药业有限公司生产、北京同仁堂（四川）健康药业有限公司（以下简称'四川健康药业'）经销"的"99%高纯南极磷虾 油"产品，相关成分涉嫌虚假标注。 针对上述情况，我公司立即责令四川健康药业停止经销该产品，并对涉事产品开展全流程核查与追溯。这款产品未经授权擅自突出使用"北京同仁堂"字 样，涉嫌违法，我们已启动司法程序，对涉事企业进行起诉，以求维护广大消费者和企业的合法权益。 同仁堂始终把产品质量与消费者健康放在首位。我们郑重承诺，公司将进一步加强管理，与广大消费者和相关各方一道，坚决抵制任何影响消费者健康、 企业品牌形象与各方合法权益的行为。 我们愿诚恳接受社会各界的监督与指导，共同维护健康有序的市场环境。在此，也郑重提醒广大消费者：请务必通过正规渠道购买"北京同仁堂"产品，并 认准"同仁堂"双龙图案商标，避免权益受损。 早前报道 最近 南极磷虾油成为健康圈的"香饽饽" 商家普遍宣传它能改善大脑功能 守护心血管、增强免疫力 号称深海馈赠的"黄金营养液" 那么"南极磷虾油里有什么？" "真的有用吗？" 南极磷虾。图源：视觉中国 ...

Investment Rating - The report indicates a strong growth potential for the bird's nest peptide industry, with a projected market expansion from 2.17 billion CNY in 2022 to 16 billion CNY by 2029, reflecting a compound annual growth rate (CAGR) of 35.47% [8][9]. Core Insights - The bird's nest peptide industry is characterized by high biological activity and absorption, driven by technological innovations and a focus on modern biotechnology to enhance product efficacy [5][6]. - The market is evolving from research exploration to industrialization, with significant growth observed since 2018, particularly in product forms and applications [7]. - Demand is primarily driven by high-income consumers seeking precise nutrition and health benefits, with brands employing multi-channel strategies to enhance market penetration [11]. Market Background - Bird's nest peptides are derived from edible bird's nests through hydrolysis, resulting in small molecular peptides with high bioactivity [5]. - The industry has transitioned from academic research to commercialization, with key technological advancements facilitating this shift [7]. Market Status - The market size is expected to grow significantly, with a CAGR of 28.62% from 2022 to 2024, and an anticipated acceleration to 35.47% from 2025 to 2029 [8][9]. - Supply is characterized by high technical barriers and concentration among leading brands, with significant reliance on patented processes for production [10]. - Demand is robust, driven by middle to high-income consumers, with brands leveraging both online and offline channels for effective market reach [11]. Market Competition - The competitive landscape is defined by leading companies like Zheng Dian Yan Wo and Yan Zhi Wu, which have established significant barriers through raw material control and proprietary technologies [13]. - The competition has evolved from product-based to a comprehensive evaluation of supply chain control, technological innovation, and multi-scenario applications [13]. - The report highlights ten recommended brands, each with unique strengths in product quality, technological innovation, and market positioning [14][15][16]. Development Trends - The industry is moving towards technological, functional, and standardized advancements, with a focus on cross-industry integration [17]. - Companies are increasingly investing in research to validate health benefits scientifically, shifting from concept marketing to evidence-based claims [17]. - The report emphasizes the importance of comprehensive capabilities in research, technology barriers, and innovative applications for future market leadership [17].

最近 南极磷虾油成为健康圈的"香饽饽" 商家普遍宣传它能改善大脑功能 守护心血管、增强免疫力 号称深海馈赠的"黄金营养液" 那么"南极磷虾油里有什么？" "真的有用吗？" 近日，上海市消费者权益保护委员会委托专业机构对市售15款热销产品进行检测后发现，一款标称"北 京同仁堂99%高纯南极磷虾油"的产品，其核心成分磷脂含量检测结果竟为零！ Cuixo 电网 汤臣倍健 社会 GNITE Swisse 北京同仁堂 vik △ 15款评测产品，图片下方标注的品牌/出品方均来自网页宣称 goodhealth Reap FUNRICH BOL 此前网上关于"同仁堂"没有双龙标的争议已经发酵。包括北京同仁堂（四川）健康药业有限公司在内的 厂家销售的所谓"同仁堂"产品，都在产品包装的显著位置使用了"北京同仁堂"字样的标识，但商标并非 传统的"同仁堂"双龙商标，而是"朕皇"等商标。这也频繁引发关于"同仁堂"产品代工和商标授权的消费 者纠纷。 本次测评中最引人关注的问题，来自一款标称由"安徽哈博药业有限公司"生产、由"北京同仁堂（四 川）健康药业有限公司"经销的"99%高纯南极磷虾油"。该产品在网页宣传中突出"高含量"、"智利进 ...

华西证券研报指出，仙乐健康25Q3经营环比改善，中国区调整效果显现。中国区业绩25Q3同比增长 20%以上，新消费客户收入占比超50%，渠道拓展成效显著，直播、MCN、私域、跨境电商新零售等表 现活跃。美洲2025年前三季度收入同比增长超20%，欧洲区25Q3收入同比增长超35%，公司海外品牌客 户及渠道拓展力持续增强。受益于国内恢复+全球发力带动收入提升叠加毛利率提升，但BF亏损+税率 波动对利润有所影响，公司综合净利率同比微降0.41pct至6.85%，相应的净利润同比提升16.20%至0.99 亿元。首次覆盖给予"买入"评级。 ...

寒冬已至，万物收藏。身体的抵御防线也正面临寒冷与干燥的悄然考验，免疫力告急、疲惫感挥之不 去。因此为身体积蓄能量、涵养元气成为冬日养生的关键所在。灵芝，自古被奉为"仙草"，承载着中华 文明对健康与长生的向往。它源自《神农本草经》，被尊为"上药"，其"扶正固本"的智慧，正与冬 季"藏养"的核心不谋而合。这朵祥瑞之草，为抵御严寒、守护安康，注入了传承千年的温暖力量。 灵芝多重滋养，构筑健康防线 灵芝作为千年养生瑰宝，其珍贵价值在《本草纲目》、《中国药典》等典籍中均有记载，这些功效价值 也与现代人所关注的免疫力、睡眠与精力等日常健康问题息息相关。 面对长期熬夜加班或精力透支后持续的疲惫感、动辄气喘的"虚"状，特别是冬天因日照缩短影响人体节 律，导致的午后精神萎靡、全身乏力等状况，《本草纲目》指出灵芝能"益心气"、"补中"，《中国药 典》也提到其对"虚劳短气"有益。这对应了传统智慧中"补气强身"的功效，如同为身体这座"能量库"进 行温和充电，帮助改善慢性疲劳，恢复日常活力好状态。 秋冬季节的干燥与寒冷也常令呼吸系统感到不适。针对"肺虚咳喘"，《中国药典》记载了灵芝"止咳平 喘"的作用，《本草纲目》也称其"益肺气"。当 ...

Core Viewpoint - The company, Kingdawei, is committed to enhancing the marketing of its health supplement brand Doctor's Best in the domestic market, leveraging its international brand identity and full industry chain advantages to increase market penetration of key products like Coenzyme Q10, magnesium tablets, and anti-aging series [2] Group 1 - The company aims to strengthen the market penetration of its key products through various strategies, including team building, adjusting assessment goals, increasing marketing investments, and developing suitable products [2] - The company plans to steadily advance the brand building and value creation of its domestic health supplement brand "Jinlexin" while further improving its brand matrix layout [2]

Core Viewpoint - The company, Jindawei, emphasizes its strong R&D and manufacturing capabilities, leveraging synthetic biology as a foundational innovation engine to create a comprehensive biological manufacturing platform driven by microbial fermentation and enzyme catalysis, supported by chemical synthesis [2] Group 1: R&D and Manufacturing Strength - The company possesses robust R&D and manufacturing capabilities [2] - It utilizes synthetic biology as a core innovation engine [2] - The company has developed a complete technology chain from molecular design to green manufacturing [2] Group 2: Product Development and Market Potential - The company focuses on innovative health product raw material development [2] - It has strategically positioned itself in product categories with significant market potential, including coenzyme Q10, algal oil omega-3, and biological sweeteners [2]

Core Viewpoint - Coenzyme Q10 is experiencing increasing market demand due to its validated health benefits in cardiovascular health and anti-aging, with applications across various sectors including dietary supplements, food additives, pharmaceuticals, and cosmetics [2] Group 1: Market Demand - The market demand for Coenzyme Q10 is on a continuous growth trend [2] - Major consumer countries for Coenzyme Q10 include developed nations such as the United States and Japan [2] - Emerging markets like China are identified as having significant potential and market space for Coenzyme Q10 [2]